News
ERAS
15.92
-6.44%
-1.10
ERAS: Promising RAS-Mutant Oncology Pipeline and China Partnership Support Buy Rating
TipRanks · 4h ago
Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies
TipRanks · 4h ago
Erasca drops 9% to $15.54 after Revolution pancreatic cancer data
TipRanks · 4h ago
Erasca falls -7.9%
TipRanks · 5h ago
Erasca falls -10.6%
TipRanks · 7h ago
Erasca Inc trading resumes
TipRanks · 7h ago
Erasca Inc trading halted, volatility trading pause
TipRanks · 7h ago
NASDAQ TRADE HALT <ERAS.O> VOLATILITY TRADING PAUSE AT 09:33 AM
Reuters · 7h ago
Weekly Report: what happened at ERAS last week (0406-0410)?
Weekly Report · 10h ago
How ERAS-0015 Trial Progress and Asia Licensing Expansion Will Impact Erasca (ERAS) Investors
Simply Wall St · 3d ago
Assessing Erasca (ERAS) Valuation After ERAS-0015 Trial Progress And Supportive FDA And Analyst Updates
Simply Wall St · 5d ago
Weekly Report: what happened at ERAS last week (0330-0403)?
Weekly Report · 04/06 10:23
ERAS Crosses Above Average Analyst Target
NASDAQ · 04/03 13:19
Erasca Chief Legal Officer Ebun Garner disposes of 80,000 shares for $1.3 million
Reuters · 04/03 13:00
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/03 07:00
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Benzinga · 03/31 13:57
Weekly Report: what happened at ERAS last week (0323-0327)?
Weekly Report · 03/30 10:23
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't
The Motley Fool · 03/26 22:04
Analysts Conflicted on These Healthcare Names: Erasca (ERAS) and Mereo Biopharma Group Plc (MREO)
TipRanks · 03/26 12:21
Erasca’s HERKULES-3 Trial Reaches Completion: What Investors Should Watch in ERAS-007
TipRanks · 03/25 16:30
More
Webull provides a variety of real-time ERAS stock news. You can receive the latest news about Erasca, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.